{
    "clinical_study": {
        "@rank": "20217", 
        "brief_summary": {
            "textblock": "In patients who are receiving intravenous high dose Interleukin-2, patients will be\n      randomized into two groups: group one will receive nystatin swish and swallow immediately\n      before initiation of IL-2, and the second group will receive a placebo.  The patients in\n      each group will be monitored and evaluated for differences in the rate and severity of\n      development of oral irritation during treatment.  They will also be studied for differences\n      between the two groups in the number of doses of IL-2 taken."
        }, 
        "brief_title": "A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2", 
        "completion_date": "August 2000", 
        "condition": [
            "Candidiasis, Oral", 
            "Gastrointestinal Diseases", 
            "Stomatitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Candidiasis", 
                "Candidiasis, Oral", 
                "Gastrointestinal Diseases", 
                "Digestive System Diseases", 
                "Stomatitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "In patients who are receiving intravenous high dose Interleukin-2, patients will be\n      randomized into two groups: group one will receive nystatin swish and swallow immediately\n      before initiation of IL-2, and the second group will receive a placebo.  The patients in\n      each group will be monitored and evaluated for differences in the rate and severity of\n      development of oral irritation during treatment.  They will also be studied for differences\n      between the two groups in the number of doses of IL-2 taken."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "All patients enrolled on high dose intravenous interleukin-2 studies in the Surgery Branch\n        of the National Cancer Institute are eligible, except for patients who are receiving\n        adoptively transferred cells (cloned peripheral blood cells).\n\n        All inclusion criteria as stated in the parent immunotherapy protocol apply:\n\n        No patients with evidence of oral irritation prior to starting therapy;\n\n        No patients with any known sensitivity to nystatin;\n\n        No patients receiving systemic antifungals;\n\n        No patients with active oral infections.\n\n        In additional, all exclusion criteria as stated in the parent immunotherapy protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "84", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001812", 
            "org_study_id": "990097", 
            "secondary_id": "99-C-0097"
        }, 
        "intervention": {
            "intervention_name": "Nystatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interleukin-2", 
                "Nystatin"
            ]
        }, 
        "keyword": [
            "Mucositis", 
            "Oral Candidiasis", 
            "Prophylaxis", 
            "Stomatitis", 
            "Swish and Swallow"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "reference": [
            {
                "PMID": "1403839", 
                "citation": "Marmary Y, Shiloni E, Katz J. Oral changes in interleukin-2 treated patients: a preliminary report. J Oral Pathol Med. 1992 May;21(5):230-1."
            }, 
            {
                "PMID": "8642530", 
                "citation": "Rodriguez-Archilla A, Urquia M, Cutando A, Asencio R. Denture stomatitis: quantification of interleukin-2 production by mononuclear blood cells cultured with Candida albicans. J Prosthet Dent. 1996 Apr;75(4):426-31."
            }, 
            {
                "PMID": "3903508", 
                "citation": "Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485-92."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001812"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 1999", 
        "study_design": "Endpoint Classification: Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2000"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}